Division of Hematology-Oncology

Ricardo C.T. Aguiar
Person
19932025
Sukeshi Patel Arora
- Department of Medicine, Division of Hematology-Oncology
- Mays Cancer Center
Person
20182025
Leyla Bojanini Molina
- Department of Medicine, Division of Hematology-Oncology
- Mays Cancer Center
Person
20192025

82 h-index
294 Article
46 Review article
14 Comment/debate
10 Chapter
More

Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity
Singh, D., Onyeagucha, B. C., Medina, D., Subbarayalu, P., Mojidra, R., Lyu, D., Bhandari, M., Timilsina, S., Pitta Venkata, P., Huang, J. Y., Nirzhor, S., Abdulsahib, S., Prochnau, J. Y., Do, C. T. P., Rajamanickam, S., Chen, Y., Taylor, A. B., Viswanadhapalli, S., Falzone, M. & Jiang, J. X. & 5 others, Sung, P. M., Zhou, D., Vadlamudi, R. K., Hromas, R. & Rao, M. K., Mar 2 2026, In: Cancer Research. 86, 5, p. 1252-1268 17 p.
Research output: Contribution to journal › Article › peer-review
Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study
Pongdee, T., Powell, D., Weis, T., Scherber, R., Green, T., Smither, A., Krishnappa, P., Carlson, K., Singh, P., Duff, S. & Sullivan, E., Jul 2026, In: Journal of Allergy and Clinical Immunology: Global. 5, 4, 100701.
Research output: Contribution to journal › Article › peer-review

Open Access
Building a Science-Driven Business: How National Institutes of Health Funding Enabled an Evidence-Based Approach to Maternal Mental Health Innovation
Huberty, J., Baez, L., McAlister, K. & Kerppola, M., 2026, In: JMIR Formative Research. 10, e85642.
Research output: Contribution to journal › Review article › peer-review

Open Access

Germline Mutations in TMEM127 Confer Susceptibility to Pheochromocytoma
Qin, Y. (Contributor), Yao, L. (Contributor) & Dahia, P. L. M. (Contributor), Gene Expression Omnibus, Jan 21 2010
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19987
Dataset
Additional file 2 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726547.v1, https://springernature.figshare.com/articles/dataset/Additional_file_2_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726547/1
Dataset
Additional file 3 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726550, https://springernature.figshare.com/articles/dataset/Additional_file_3_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726550
Dataset